Results 111 to 120 of about 1,031,881 (358)

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Government Analysis of the Benefits and Costs of Regulation [PDF]

open access: yes
Recently, Congress has shown a greater interest in assessing the economic impact of regulation. The interest is driven in part by estimates that federal regulation cost several hundred billion dollars annually.
Hahn, Robert W.
core   +1 more source

A cost analysis of medicine donation programs to Tanzania’s neglected tropical diseases control program [PDF]

open access: yes, 2019
Masters of Public Health - see Magister Public HealthOverreliance on donor supported health programs has crippled many African countries and there is inadequate long-term planning on the future sustainability of health systems.
Rassa, Adam Omary
core  

Lack of cost analysis [PDF]

open access: yesThe Annals of The Royal College of Surgeons of England, 2010
Although this study highlights improvements in speed of treatment delivery, the suggested benefits of cost-reduction had no costing data at all. There were no comments on additional costs, such as time to review referral letters, send out Boston questionnaires and book them into the one-stop clinic. I assume that the clinical assessment of the patients
openaire   +2 more sources

Direct and indirect cost of attempted suicide in a general hospital: cost-of-illness study

open access: yesSão Paulo Medical Journal
CONTEXT AND OBJECTIVE: Knowledge of socioeconomic impact of attempted suicide may sensitize managers regarding prevention strategies. There are no published data on this in Brazil.
Sara Maria Teixeira Sgobin   +3 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

The Full Cost of Intercity Highway Transportation [PDF]

open access: yes
In this paper we review the theoretical and empirical literature on the cost structure of the provision of intercity highway transportation and specify and estimate our own cost functions .
David Gillen, David Levinson
core  

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

open access: yesMolecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

An Analysis of the Eighth Government Report On the Costs and Benefits of Federal Regulations [PDF]

open access: yes
This paper critically reviews the draft of the Office of Management and Budget's eighth report on the benefits and costs of federal regulation. The draft report offers two modest improvements over previous reports.
Hahn, Robert W.   +2 more
core   +1 more source

Cost-effectiveness in clinical trials : using multiple imputation to deal with incomplete cost data [PDF]

open access: yes, 2007
Background: Cost-effectiveness has become an important outcome in many clinical trials and has resulted in the collection of resource use data and the calculation of costs for individual patients.
Burton, Andrea   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy